Q3 Sales Drop 23% to $6.5M as GLP-1 Revenue Disappears
HEWA sits 54% above its 52-week low of $0.058.
Summary
Q3 2026 net sales fell 23% year over year to $6.5M, and the net loss widened to $240K from $72K a year earlier. Adjusted EBITDA stayed positive at $123K but dropped from $384K, so the business is still earning on an operating basis, just far less. The revenue hole is the loss of compounded GLP-1 sales after FDA shortage determinations ended the company's ability to offer those products — a structural removal of a product line, not a demand blip. Gross margin rose 12.4 points to 55.1%, which cushioned but did not offset the sales decline. For a micro-cap at roughly $5M market value, a 23% top-line drop with a widening loss is the whole story; the question is whether OTC and other product growth can replace the GLP-1 revenue before cash earnings erode further.
At the time of this announcement, HEWA was trading at $0.09 on OTC in the Trade & Services sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.06 to $0.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.